Record Third Quarter Revenue
Vericel achieved record third quarter revenue of approximately $58 million, a 27% increase compared to the previous year, exceeding their guidance for the quarter.
Significant Margin Expansion
The company reported a gross profit of $41.7 million, or 72% of net revenue, an increase of 480 basis points compared to 2023.
Regulatory Milestones Achieved
Vericel received FDA approval for MACI Arthro and the NexoBrid pediatric indication, positioning the company for future growth.
Strong Burn Care Revenue Growth
Total Burn Care revenue in the third quarter grew 66% to $13.2 million, driven by record quarterly Epicel revenue of $12.2 million.
Positive Adjusted EBITDA Growth
Adjusted EBITDA for the quarter increased 84% to $10 million, or 17% of revenue, an increase of over 500 basis points versus the prior year.
Strong Cash Position
The company generated over $10 million of operating cash flow and ended the third quarter with $151 million in cash, restricted cash, and investments with no debt.